(Stroke. 1999;30:1628-1631.)
© 1999 American Heart Association, Inc.
Original Contributions |
From the Departments of Neurology (J.S.P. van den B., M.L.), Pediatrics (R.C.M.H.), and Neurosurgery (K.W.A.) and Institute for Human Genetics (R.C.M.H., A.W.), University of Amsterdam, Academic Medical Center; Department of Human Genetics, Vrije Universiteit, Amsterdam (G.P., F.A.); and Department of Neurology, University of Nijmegen, University Hospital Nijmegen (J.S.P. van den B.) (Netherlands).
Correspondence to J.S.P. van den Berg, Department of Neurology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, Netherlands. E-mail J.vandenberg{at}czzoneu.azn.nl
| Abstract |
|---|
|
|
|---|
MethodsWe analyzed the type III collagen gene in a group of 41 consecutive patients with an intracranial aneurysm, of whom 6 patients had shown a reduced production of type III collagen in cultured diploid fibroblasts from a skin biopsy.
ResultsNo mutations could be demonstrated in the COL3A1 gene, especially not in the globular N- and C-terminal regions. A null allele was excluded in 25 patients, including 1 patient with a decreased type III collagen production. No differences were found between 41 patients and 41 controls in allele frequencies of a DNA tandem repeat polymorphism located in the COL3A1 gene.
ConclusionsIt is concluded that the COL3A1 gene is not directly involved in the pathogenesis of most of intracranial aneurysms. The reduced type III collagen production in cultured fibroblasts found in some patients with an intracranial aneurysm is not explained by the present study and needs further exploration.
Key Words: cerebral aneurysm collagen pathology
| Introduction |
|---|
|
|
|---|
No deficiency of type III collagen production was observed in 5 patients with familial intracranial aneurysms.11 12 However, several studies have suggested that type III collagen deficiency is a risk factor for intracranial aneurysms.13 14 15 16 17 In none of these studies was there a molecular analysis of the type III collagen gene, except for the study performed by Kuivaniemi and coworkers,18 who analyzed part of the type III procollagen gene encoding the triple helix. In 40 patients, no mutations were found in this part of the gene.
In a previous protein study we observed a decreased production of type III collagen in cultured skin fibroblasts from 6 of 41 consecutive patients with intracranial aneurysms and in none of a group of 41 age- and sex-matched healthy controls.19 Here we present molecular analysis of the complete COL3A1 gene, including the regions encoding the globular N- and C-terminal parts of the protein. Mutations in the C-propeptide may affect or even prevent triple helix formation as well as protein stability, and mutations in the N-propeptide may affect the function of type III collagen by preventing removal of the N-propeptide. The propeptide regions were not analyzed in the previous study by Kuivaniemi et al.18
Patients with a normal level of type III collagen were also studied. It is possible that patients with mild forms of Ehlers-Danlos syndromevascular type have normal production of a structurally altered type III collagen as a result of a mutation of the COL3A1 gene.20
In Ehlers-Danlos syndromevascular type, inactive gene copies (null alleles) of COL3A1 result in a mild form of the disorder.21 To determine whether both COL3A1 alleles were active, we investigated whether polymorphisms in the 3'-untranslated part of type III collagen were present. Null alleles, which do not produce stable mRNA, lead to a low level of gene product.
Brega et al22 investigated allele frequencies for type III collagen gene using an Ava II polymorphism (restriction fragment length polymorphism) in 19 patients with an intracranial aneurysm and in 15 controls. A diallelic polymorphism with fragments of 5.7 kb (allele A) and 4.3 kb (allele B) was found. Allele B was demonstrated in 11 patients and in only 2 controls. This polymorphism is located in an intron of the gene and probably has no biological effect. This association could indicate linkage disequilibrium with a mutation in the COL3A1 gene, which may occur when a mutation has arisen in a gene close to a DNA marker with a certain allele. If the mutation spreads through the population, it remains associated with this allele. If this would be the case, a subgroup of patients in whom type III collagen is involved in the formation of intracranial aneurysms should be identified by a specific allele of the linked polymorphism. These disequilibrium data suggest that an abnormal type III collagen is involved in the formation of some intracranial aneurysms. We studied a more polymorphic and informative DNA tandem repeat polymorphism in the COL3A1 gene.23
| Subjects and Methods |
|---|
|
|
|---|
Reverse Transcription
Total RNA was isolated from 1x106
cultured fibroblasts with the use of RNAzol (Life Technologies,
Bethesda, Md) according to the manufacturer`s instructions.
First-strand cDNA was prepared with oligo-dTcoated magnetic beads
(Dynal AS, Oslo, Norway) to capture the mRNA, according to the method
of Raineri et al.24 Reverse transcription was performed on
the captured mRNA after washing of the beads with the use of the
oligo-dT on the beads as primer and Superscript II reverse
transcriptase (Life Technologies, Bethesda, Md).
DNA Analysis
The COL3A1 gene was analyzed on cDNA produced
from cultured skin fibroblast RNA. In all patients the region of the
gene encoding the triple helix was screened with single-strand
conformation polymorphism (SSCP) and heteroduplex analysis,
followed by DNA sequencing of aberrant fragments. The regions encoding
the N- and C-terminal parts were sequenced in all patients.
SSCP/heteroduplex analysis was also performed on genomic DNA
and cDNA in the 3'-untranslated region of COL3A1 to detect
polymorphic sites. If a patient was heterozygous for a
polymorphism, this was used to determine expression of both gene
copies in the cDNA.
Polymerase Chain ReactionSSCP/ Heteroduplex Analysis
Polymerase chain reactions (PCR) were performed on the
immobilized cDNA to amplify the type III collagen cDNA in
20 overlapping fragments for SSCP/heteroduplex mutation
analysis and DNA sequencing. For SSCP/heteroduplex
analysis, fragments of
350 bp were used. These fragments
were analyzed on polyacrylamide minigels in an
automated electrophoresis system (Phastsystem, Pharmacia, Upsala,
Sweden).25 If a sample yielded additional bands in the
single-stranded (SSCP) or double-stranded (heteroduplex) area of the
gel, the region of the gene containing this fragment was subjected to
sequence analysis. PCR primer sequences and reaction conditions
are available upon request from one of the authors (G.P.).
DNA Sequencing
For DNA sequence analysis, PCR products were made
with cDNA and/or genomic DNA primer sets, of which the primer was
5'-biotin labeled. Single-stranded DNA was prepared with
streptavidin-coated Dynabeads (Dynal, Oslo, Norway) according to the
manufacturer's instructions. Dideoxy sequencing reactions with a
Pharmacia T7 sequencing kit (Pharmacia, Upsula, Sweden) were performed
on the sense strand of the PCR products on the Dynabeads and on the
antisense strand that was washed off the Dynabeads and ethanol
precipitated. Specific sequencing primers were used for each PCR
fragment.35S-labeled dCTP was used to detect the
products by autoradiography after electrophoresis
on 6% denaturing polyacrylamide gels.
C to T Polymorphism in Exon 33 of the
COL3A1 Gene
To detect whether polymorphisms were present in exon 33,
a restriction analysis according to Tromp et al26
was used.
DNA Marker in Intron 25 of the COL3A1 Gene
Mays et al23 described a 15-base DNA tandem repeat
marker in intron 25 of COL3A1, and we studied this marker
using CY5-labeled dCTP in the PCR reaction to label the PCR
products. The estimated length of the alleles was assessed on
an ALFExpress automated DNA sequencer (Pharmacia, Upsala, Sweden) and
corresponded to an apparent repeat length of 16 bp.
Statistical Analysis
For comparison of allele frequencies, we calculated the
difference, with 95% CI limits, using Fisher's exact
test.27
| Results |
|---|
|
|
|---|
After performing SSCP/heteroduplex analysis of PCR-amplified
fragments from the part of the cDNA encoding the triple helix of type
III collagen of all patients, we detected a fragment with an altered
electrophoretic mobility in only 1 patient. The cultured fibroblasts of
this patient previously showed a decreased synthesis of type III
collagen.19 To characterize the nucleotide
sequence of the altered fragment of this patient, DNA sequencing was
performed. The data showed a T
C change at position 2793 (numbering
according to Ala-Kokko et al28 ). This was confirmed in
genomic DNA. However, the T
C change is a silent mutation and does
not lead to an amino acid substitution of type III procollagen.
Polymorphisms in exon 33 were detected in 16 of the 40 patients by
a restriction analysis according to the method of Tromp et
al.26
To determine whether both copies of the gene produced stable RNA, we looked for polymorphisms in the 3'-untranslated part of type III collagen. SSCP/heteroduplex analysis of PCR-amplified fragments of the untranslated part of type III collagen showed heterozygosity in 25 of the 41 patients; 1 of them was shown earlier to have a decreased type III collagen production.19
In all 25 patients the heterozygous polymorphism could also be demonstrated in the cDNA, indicating that both alleles of COL3A1 were expressed and produced stable mRNA.
To investigate abnormal allele frequency in the type III collagen
gene, we used a highly variable, tandem repeat marker in intron 25
of the COL3A1 gene with 6 alleles. We found no
difference in allele frequency in our patients compared with the
control group (Table
), nor was a
difference in allele frequency found in patients with decreased
type III collagen production compared with patients with normal
production.
|
| Discussion |
|---|
|
|
|---|
SSCP/heteroduplex analysis, screening the complete type III
collagen coding sequence, showed only 1 silent mutation (2793T
C),
which does not lead to a change in the amino acid sequence. This result
is in agreement with data presented by Kuivaniemi et
al,18 who observed no mutations when sequencing the
triple-helix encoding part of the type III procollagen gene in 40
patients with intracranial aneurysms. However, in this study
the N-propeptide part or the C-propeptide part of the type III collagen
gene was not analyzed. The globular part of the C-propeptide is
essential for the formation of the triple helix in fibrillar
collagens.29,30 A mutation in the C-terminal part
may theoretically lead to a failure of association of the procollagen
monomers with an intracellular breakdown of the mutated pro-
1 chain,
or it may lead to an abnormal association with all 3
1 chains being
destroyed.31 Therefore, the C-propeptide of the type III
collagen gene was sequenced, showing no changes. Our data strengthen
the conclusion of the study of Kuivaniemi et al18 that the
type III collagen gene is not likely to be involved in the formation of
intracranial aneurysms. In the collagen mutation database, 3%
of the mutations are large deletions.32 Single or
multi-exon deletions can be demonstrated in cDNA, as we found in our
collagen mutation studies (J.S.P. van den Berg, MD, et al, unpublished
data, 1999). Large PCR products from cDNA in these patients
did not show evidence of deletions or exon skipping. However, we may
have missed any large deletions that encompass the entire gene or lead
to unstable messenger RNA.
Null alleles leading to reduced type III collagen secretion have been described.21 These patients showed a normal or mild clinical phenotype.21 In 25 patients, including 1 patient with decreased production of type III collagen, the presence of a null allele could be excluded, making it unlikely to be a major contributor to the phenotype in this study group.
In none of the 6 patients with an intracranial aneurysm and a decreased level of type III collagen was a mutation in the type III collagen found with SSCP/heteroduplex. SSCP analysis, with PCR fragments of 350 nucleotides, detects >80% of the mutations.33 34 Combining SSCP with heteroduplex analysis will lead to a higher detection rate. However, polymorphisms in exon 33 were detected with a restriction analysis according to Tromp et al26 and not with SSCP/heteroduplex analysis.
The Ehlers-Danlos syndromevascular type phenotype varies from classic ("acrogeric") presentation to almost no visible abnormalities ("atypical").35 In patients with classic Ehlers-Danlos syndromevascular type, mutations in the type III collagen gene are frequently detected, but they are often not found in the atypical form of the disease.36 Our patients with decreased production of type III collagen may be considered to have atypical Ehlers-Danlos syndromevascular type. The decreased production of type III collagen in patients with this syndrome may be due to defects during posttranslational modification or altered collagen metabolism, eg, elevated gelatinase activity.37
The reported association of intracranial aneurysms with type III collagen polymorphism22 was not confirmed in the present study, since none of the 6 alleles of a highly variable marker showed a difference in frequency in the patients compared with the control group. This shows that, at least in the Dutch population, there is no indication of linkage disequilibrium in the region of COL3A1. It is therefore unlikely that a single mutation in this gene plays a role in susceptibility to intracranial aneurysms.
Although reduced production of type III collagen is a contributory factor in the formation of intracranial aneurysms in some patients, determination of the exact causative molecular mechanisms of this aberration awaits further studies.
| Acknowledgments |
|---|
Received December 11, 1998; revision received May 6, 1999; accepted May 6, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y.B.W.E.M. Roos, G. Pals, P.M. Struycken, G.J.E. Rinkel, M. Limburg, J.C. Pronk, J.S.P. van den Berg, J.A.F.M. Luijten, P.L. Pearson, M. Vermeulen, et al. Genome-Wide Linkage in a Large Dutch Consanguineous Family Maps a Locus for Intracranial Aneurysms to Chromosome 2p13 Stroke, October 1, 2004; 35(10): 2276 - 2281. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ribourtout and J. Raymond Gene Therapy and Endovascular Treatment of Intracranial Aneurysms Stroke, March 1, 2004; 35(3): 786 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Krex, H. Rohl, I. R. Konig, A. Ziegler, H. K. Schackert, and G. Schackert Tissue Inhibitor of Metalloproteinases-1, -2, and -3 Polymorphisms in a White Population With Intracranial Aneurysms Stroke, December 1, 2003; 34(12): 2817 - 2821. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hofer, M. Hermans, N. Kubassek, M. Sitzer, H. Funke, F. Stogbauer, V. Ivaskevicius, J. Oldenburg, J. Burtscher, U. Knopp, et al. Elastin Polymorphism Haplotype and Intracranial Aneurysms Are Not Associated in Central Europe Stroke, May 1, 2003; 34(5): 1207 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamada, M. Utsunomiya, K. Inoue, K. Nozaki, S. Miyamoto, N. Hashimoto, K. Takenaka, T. Yoshinaga, and A. Koizumi Absence of Linkage of Familial Intracranial Aneurysms to 7q11 in Highly Aggregated Japanese Families Stroke, April 1, 2003; 34(4): 892 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.J. Hademenos, M.J. Alberts, I. Awad, M. Mayberg, T. Shephard, A. Jagoda, R.E. Latchaw, H.W. Todd, K. Viste, R. Starke, et al. Advances in the genetics of cerebrovascular disease and stroke Neurology, April 24, 2001; 56(8): 997 - 1008. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |